MedTrace Logo

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

NCT03062800 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2019-06-05

No results posted yet for this study

Summary

The study for innovative strategies is warranted in the treatment of advanced non-squamous NSCLC with epidermal growth factor receptor wild-type or unknown mutation status because the outcomes remain unsatisfactory for most patients. Maintenance treatment after first-line chemotherapy is a very interesting strategy that has been largely investigated in the last years. This study is to evaluate the efficacy and toxicity of thalidomide in combination with chemotherapy and as maintenance treatment in patients with advanced non-squamous NSCLC.

Conditions

  • Advanced Nsclc

Interventions

DRUG

Thalidomide

100-200mg/d,oral ,qn

DRUG

pemetrexed

(500mg/m\^2) on day 1 of 21-days cycle,ivgtt

DRUG

cisplatin

(75mg/m\^2) on day 1 of 21-days cycle, ivgtt

DRUG

carboplatin

(AUC=5) on day 1 of 21-days cycle, ivgtt

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Xiuwen Wang, MD.PhD · Qilu Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-12-31
Completion
2021-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062800 on ClinicalTrials.gov